Agentes dopaminérgicos e o tratamento da disfunção erétil
dc.contributor.author | Neves, Gilda Angela | pt_BR |
dc.contributor.author | Rates, Stela Maris Kuze | pt_BR |
dc.contributor.author | Fraga, Carlos Alberto Manssour | pt_BR |
dc.contributor.author | Barreiro, Eliezer J. | pt_BR |
dc.date.accessioned | 2013-07-03T01:42:55Z | pt_BR |
dc.date.issued | 2004 | pt_BR |
dc.identifier.issn | 0100-4042 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/72989 | pt_BR |
dc.description.abstract | The understanding of the scientific basis of the erectile function expanded rapidly the range of therapies for treating erectile dysfunction in recent years. This article reviews the role of dopamine on the erection mechanisms and its importance for new pro-erectile drug design. The ability of dopaminergic agents to elicit penile erection has been described since 1975 and successively confirmed by numerous studies. The development of apomorphine SL (dopaminergic non selective agonist) to enhance erectile function represents a new pharmacological approach to the management of erectile dysfunction using CNS drugs. The search for selective D4 dopaminergic agents is being explored by some research groups and pharmaceutical companies. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | por | pt_BR |
dc.relation.ispartof | Química nova. São Paulo. Vol. 27, n. 6 (2004), p. 949-957 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Erectile dysfunction | en |
dc.subject | Disfunção erétil : tratamento | pt_BR |
dc.subject | Dopaminergic agents | en |
dc.subject | Agentes dopaminérgicos | pt_BR |
dc.subject | Apomorphine | en |
dc.title | Agentes dopaminérgicos e o tratamento da disfunção erétil | pt_BR |
dc.title.alternative | Dopaminergic agents and erectile dysfunction treatment | en |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000608830 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (40305)Ciências da Saúde (10773)